The invention relates to a Cu(1) complex of Formula (I), wherein L is a ligand of Formula (II), wherein n1, n2, n3 are independently to each other, an integer from 0 to 1, A1, A2 and A3 are independently from each other,a phenyl optionally substituted with (C.sub.1-C.sub.3)alkoxy, (C.sub.1-C.sub.3)alkyl, F, formyl, carboxyl, sulphonyl hydroxyl, hydroxyl, methoxy(C.sub.1-C.sub.3)alkoxy oran heterocyclic ring selected from piperazinyl, morpholynyl, thiomorpholynyl, optionally substituted with (C.sub.1-C.sub.3)alkyl, where the heterocyclic ring is linked with the nitrogen atom to CH.sub.2 residue, with the proviso that when A1, A2 or A3 is optionally substituted phenyl, then n1, n2 or n3, respectively, is 0, and when A1, A2 or A3 is optionally substituted heterocyclic ring, then n1, n2 or n3, respectively, is 1, for use in the treatment of tumours.

Lanthionine ketimine derivatives, and methods of making and using the same, are described. Included are lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P) derivatives, as well as lanthionine ketimine derivatives having a tert-enamide moiety at the 2-position (NVP-LKE).

Lanthionine ketimine derivatives, and methods of making and using the same, are described. Included are lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P) derivatives, as well as lanthionine ketimine derivatives having a tert-enamide moiety at the 2-position (NVP-LKE).

A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein: P.sup.X is selected from the group consisting of (P1), (P2) and (P3).

##STR00001##

A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.

##STR00001##

The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.

The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.

The present invention aims to provide an additive for a non-aqueous electrolyte solution with excellent storage stability capable of forming a stable SEI on the surface of an electrode to improve cell performance such as a cycle performance, a discharge/charge capacity, and internal resistance, when the additive is used for electrical storage devices such as non-aqueous electrolyte solution secondary cells and electric double layer capacitors. The present invention also aims to provide a non-aqueous electrolyte solution containing the additive for a non-aqueous electrolyte solution and to provide an electrical storage device using the non-aqueous electrolyte solution. The present invention is an additive for a non-aqueous electrolyte solution, comprising a compound that has a structure represented by the formula (1-1) or (1-2): ##STR00001##
in which A represents C.sub.mH.sub.(2mn)Z.sub.n, m being an integer of 1 to 6, n being an integer of 0 to 12, and Z representing a substituted or unsubstituted alkyl group, a silyl group, a phosphonic acid ester group, an acyl group, a cyano group, or a nitro group, the compound having a lowest unoccupied molecular orbital energy of 3.0 to 0.4 eV, a standard enthalpy of formation of 220 to 40 kcal/mol, and an enthalpy change with hydrolysis reaction of 5 to 5 kcal/mol.

The present invention aims to provide an additive for a non-aqueous electrolyte solution with excellent storage stability capable of forming a stable SEI on the surface of an electrode to improve cell performance such as a cycle performance, a discharge/charge capacity, and internal resistance, when the additive is used for electrical storage devices such as non-aqueous electrolyte solution secondary cells and electric double layer capacitors. The present invention also aims to provide a non-aqueous electrolyte solution containing the additive for a non-aqueous electrolyte solution and to provide an electrical storage device using the non-aqueous electrolyte solution. The present invention is an additive for a non-aqueous electrolyte solution, comprising a compound that has a structure represented by the formula (1-1) or (1-2): ##STR00001##
in which A represents C.sub.mH.sub.(2mn)Z.sub.n, m being an integer of 1 to 6, n being an integer of 0 to 12, and Z representing a substituted or unsubstituted alkyl group, a silyl group, a phosphonic acid ester group, an acyl group, a cyano group, or a nitro group, the compound having a lowest unoccupied molecular orbital energy of 3.0 to 0.4 eV, a standard enthalpy of formation of 220 to 40 kcal/mol, and an enthalpy change with hydrolysis reaction of 5 to 5 kcal/mol.

The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.